HK10293A - Ligands and methods for augmenting b-cell proliferation - Google Patents

Ligands and methods for augmenting b-cell proliferation Download PDF

Info

Publication number: HK10293A
Authority: HK; Hong Kong
Prior art keywords: cell proliferation; ligands; augmenting; methods; proliferation
Prior art date: 1986-06-13

Application number

HK102/93A

Other languages

English (en)

Inventor

A Ledbetter Jeffrey

A Clark Edward

Original Assignee

Oncogen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-13

Filing date

1993-02-11

Publication date

1993-02-19

1993-02-11 Application filed by Oncogen filed Critical Oncogen

1993-02-19 Publication of HK10293A publication Critical patent/HK10293A/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

HK102/93A 1986-06-13 1993-02-11 Ligands and methods for augmenting b-cell proliferation HK10293A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US87388486A	1986-06-13	1986-06-13

Publications (1)

Publication Number	Publication Date
HK10293A true HK10293A (en)	1993-02-19

Family

ID=25362524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK102/93A HK10293A (en)	1986-06-13	1993-02-11	Ligands and methods for augmenting b-cell proliferation

Country Status (22)

Country	Link
JP (1)	JPH0762040B2 (fr)
KR (1)	KR910004100B1 (fr)
AT (1)	AT398437B (fr)
AU (1)	AU617087B2 (fr)
BE (1)	BE1000587A4 (fr)
CA (1)	CA1338781C (fr)
CH (1)	CH676600A5 (fr)
CY (1)	CY1681A (fr)
DE (1)	DE3719398C2 (fr)
DK (1)	DK173940B1 (fr)
FR (1)	FR2607136B1 (fr)
GB (1)	GB2191494B (fr)
GR (1)	GR870930B (fr)
HK (1)	HK10293A (fr)
IE (1)	IE60486B1 (fr)
IL (1)	IL82841A (fr)
IT (1)	IT1208649B (fr)
LU (1)	LU86919A1 (fr)
NL (1)	NL195022C (fr)
PT (1)	PT85073B (fr)
SE (1)	SE504675C2 (fr)
SG (1)	SG118992G (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506126A (en) *	1988-02-25	1996-04-09	The General Hospital Corporation	Rapid immunoselection cloning method
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
CO4600681A1 (es)	1996-02-24	1998-05-08	Boehringer Ingelheim Pharma	Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4443427A (en) *	1982-06-21	1984-04-17	Sidney Farber Cancer Institute, Inc.	Monoclonal antibody
EP0117705A3 (fr) *	1983-02-24	1985-09-25	The Regents Of The University Of California	Anticorps monoclonal spécifique des monocytes et des cellules blastiques
FR2547731A1 (fr) *	1983-06-27	1984-12-28	Centre Nat Rech Scient	Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) *	1983-12-14	1986-04-29	Dana-Farber Cancer Institute, Inc.	Monoclonal antibody with specificity to human small cell carcinoma and use thereof

1987
- 1987-06-10 BE BE8700641A patent/BE1000587A4/fr not_active IP Right Cessation
- 1987-06-10 IL IL82841A patent/IL82841A/xx not_active IP Right Cessation
- 1987-06-11 GB GB8713650A patent/GB2191494B/en not_active Expired - Lifetime
- 1987-06-11 DE DE3719398A patent/DE3719398C2/de not_active Expired - Lifetime
- 1987-06-12 KR KR1019870005969A patent/KR910004100B1/ko not_active Expired
- 1987-06-12 PT PT85073A patent/PT85073B/pt unknown
- 1987-06-12 JP JP62146811A patent/JPH0762040B2/ja not_active Expired - Lifetime
- 1987-06-12 NL NL8701371A patent/NL195022C/nl not_active IP Right Cessation
- 1987-06-12 IT IT8720899A patent/IT1208649B/it active
- 1987-06-12 SE SE8702463A patent/SE504675C2/sv not_active IP Right Cessation
- 1987-06-12 DK DK198703022A patent/DK173940B1/da not_active IP Right Cessation
- 1987-06-12 IE IE156387A patent/IE60486B1/en not_active IP Right Cessation
- 1987-06-12 FR FR878708245A patent/FR2607136B1/fr not_active Expired
- 1987-06-12 CA CA000539506A patent/CA1338781C/fr not_active Expired - Lifetime
- 1987-06-12 LU LU86919A patent/LU86919A1/fr unknown
- 1987-06-15 AT AT0151387A patent/AT398437B/de not_active IP Right Cessation
- 1987-06-15 AU AU74214/87A patent/AU617087B2/en not_active Expired
- 1987-06-15 GR GR870930A patent/GR870930B/el unknown
- 1987-06-15 CH CH2240/87A patent/CH676600A5/de not_active IP Right Cessation
1992
- 1992-11-10 SG SG1189/92A patent/SG118992G/en unknown
1993
- 1993-02-11 HK HK102/93A patent/HK10293A/xx not_active IP Right Cessation
- 1993-10-10 CY CY1681A patent/CY1681A/en unknown

Also Published As

Publication number	Publication date
IE60486B1 (en)	1994-07-27
FR2607136A1 (fr)	1988-05-27
AU7421487A (en)	1987-12-17
IL82841A0 (en)	1987-12-20
DK302287A (da)	1987-12-14
CY1681A (en)	1993-10-10
DK302287D0 (da)	1987-06-12
IE871563L (en)	1987-12-13
DE3719398A1 (de)	1988-01-28
SE504675C2 (sv)	1997-04-07
DE3719398C2 (de)	1996-03-28
KR880000582A (ko)	1988-03-28
CA1338781C (fr)	1996-12-10
LU86919A1 (fr)	1989-03-08
NL8701371A (nl)	1988-01-04
ATA151387A (de)	1994-04-15
BE1000587A4 (fr)	1989-02-14
GB2191494B (en)	1990-08-22
FR2607136B1 (fr)	1989-09-15
IT1208649B (it)	1989-07-10
SE8702463L (sv)	1987-12-14
IL82841A (en)	1992-11-15
SG118992G (en)	1993-01-29
AU617087B2 (en)	1991-11-21
CH676600A5 (fr)	1991-02-15
JPS6480299A (en)	1989-03-27
SE8702463D0 (sv)	1987-06-12
JPH0762040B2 (ja)	1995-07-05
DK173940B1 (da)	2002-03-04
PT85073B (pt)	1990-07-31
KR910004100B1 (ko)	1991-06-22
GR870930B (en)	1987-12-16
GB8713650D0 (en)	1987-07-15
AT398437B (de)	1994-12-27
GB2191494A (en)	1987-12-16
PT85073A (en)	1987-07-01
NL195022C (nl)	2003-06-18
IT8720899A0 (it)	1987-06-12

Legal Events

Date	Code	Title	Description
2004-12-15	PF	Patent in force
2007-07-13	PE	Patent expired	Effective date: 20070610

Publication	Publication Date	Title
DE3380697D1 (en)	1989-11-16	Monoclonal antibody
IL76142A0 (en)	1985-12-31	Monoclonal antibody specific to human carcinoma tumorassociated antigen,hybrid cell lines producing the same and methods for the use thereof
AU2460988A (en)	1989-05-04	Simultaneous immunoassay for the determination of antigens and antibodies
AU616156B2 (en)	1991-10-24	Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
IL68941A0 (en)	1983-10-31	Method for immobilizing biological materials,composite materials produced thereby and their use
EP0376746A3 (fr)	1990-08-22	Famille de gènes pour des antigènes associés à des tumeurs
AU4493685A (en)	1986-01-10	Polyclonal antibodies, preparation and use
PL298158A1 (en)	1994-01-10	Bonding composition for obtaining novel agglomerate based on disinteghrated materials, method of using such composition and novel agglomerate obtained thereby
HUT38391A (en)	1986-05-28	Process for preparing new monoclonal antibodies against glycoconjugates and for the utilization thereof
GB2213830B (en)	1991-10-23	Water-resistant fuel agglomerate, process for preparing it and composition of matter employed in the process
AU6927287A (en)	1987-08-27	Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas
AU3657693A (en)	1993-09-01	Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and use therfor
GB2191577B (en)	1990-08-01	Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen
EP0240344A3 (en)	1989-08-16	Monoclonal antibodies and their use
AU2097592A (en)	1992-10-29	Fibrinogen-specific monoclonal antibody and uses thereof
AU3529889A (en)	1989-10-12	Specific cea-family antigens, antibodies specific and their methods of use
AU2895489A (en)	1989-08-10	Gene fragments coding for anti-hiv antibody variable region, anti-hiv chimeric antibody expressed using the same, and process for preparation thereof
GB2153364B (en)	1987-09-23	Lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
AU616667B2 (en)	1991-11-07	Monoclonal antibodies against e7 protein of human type 16 papillomavirus, a process for their preparation, and their use
AU8944291A (en)	1992-06-11	Immunoassay for the determination of anti-hiv antibodies in human samples
AU1042488A (en)	1988-07-15	Bilirubin antigen, monoclonal antibody therefor, process for their preparation, and their use
SE8702463D0 (sv)	1987-06-12	Ligands and methods for augmenting b-cell proliferation
AU4970885A (en)	1986-05-15	Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
IL83342A0 (en)	1987-12-31	Monoclonal antibodies,their preparation and their use
AU8305287A (en)	1988-06-30	Solid fuel-water slurry composition and process for the preparation of the same